Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company that specializes in discovering and developing therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. Its lead product candidate, inarigivir soproxil, is aimed at treating chronic hepatitis B virus. The company also has other SMNH product candidates in its pipeline, including an immunotherapeutic agent to potentially treat certain cancers. Spring Bank Pharmaceuticals has a strategic partnership with Gilead Sciences to conduct a Phase II trial on the combination of inarigivir and tenofovir alafenamide for HBV patients. The company was founded in 2002 and is headquartered in Massachusetts.
Spring Bank Pharmaceuticals, Inc.'s ticker is SBPH
The company's shares trade on the NASDAQ stock exchange
They are based in Hopkinton, Massachusetts
There are 11-50 employees working at Spring Bank Pharmaceuticals, Inc.
It is https://springbankpharm.com/
Spring Bank Pharmaceuticals, Inc. is in the Healthcare sector
Spring Bank Pharmaceuticals, Inc. is in the Biotechnology industry
The following five companies are Spring Bank Pharmaceuticals, Inc.'s industry peers: